Remepy
Remepy is a digital health startup specializing in hybrid drugs that combine traditional medications with digital interventions. The company focuses on improving treatment outcomes for chronic diseases such as Parkinson's and cancer through personalized therapies. Their innovative approach integrates therapeutic mobile applications with pharmacological treatments, targeting both disease symptoms and patient well-being.
Headcount
Website visitors
Workforce
Headcount by location
- Israel91%
- United States8.8%
Split by department
- Engineering & R&D37%
- Healthcare16%
- Operations9.0%
- Finance & Administration7.5%
- Other30%
Seniority distribution
- Less than 5 years75%
- 10 to 20 years10%
- 30 years and more5.8%
- 5 to 10 years5.8%
- 20 to 30 years2.9%
Funding
Raised to date
- 12 Aug 2026Series A$36.0MFresh Fund, IT-Farm Corporation, Key1 Capital, Merck, M Ventures, Nfx, O.G. Venture Partners, Qumra Capital, TechAviv, Vine Ventures
One earlier round, with its terms and sources.
Investors
NfxNFX is a venture capital firm that specializes in early-stage investments in technology-driven startups. They provide funding, strategic support, and educational resources to founders in sectors like gaming, generative AI, and fintech. NFX aims to279United States
Samsung NextSamsung Next is a venture capital firm that invests in technology sectors such as Artificial Intelligence, Healthtech, and Consumer Services. The company supports ambitious founders by providing funding and resources to help them develop innovative252United States
MerckMerck & Co., Inc. is a global biopharmaceutical company that discovers, develops, manufactures and markets human medicines, vaccines and animal health products. It serves patients, healthcare providers, veterinarians, governments and NGOs worldwide212United States
M VenturesM Ventures is a venture capital firm that invests in transformational ideas within the biotechnology and technology sectors. It focuses on supporting entrepreneurs and innovative companies by providing capital and strategic insights to help them102The Netherlands
Revenue
EBITDA
Revenue source: Modeled estimate
Recent news
- Remepy welcomes pharma R&D leader, Eran Harary, MD, as Chief Medical Officer, to advance Hybrid Drug(TM) pipeline.hires
- Remepy raises $36M Series A.invests into
- Remepy raises $36 million to advance Hybrid Drug pipeline.invests into
- Funding roundup: Silence Therapeutics, AbCellera announce IPO pricing, Beyang, Remepy close Series A financing.is developing
People
How the team has changed month by month — joiners, leavers and where the hiring is going
Connections
Who at your firm already knows someone here, and how warm the path is
The full Remepy profile lives in Inven.
Your competitors are already on Inven
See how Inven turns hours of manual research into a single, structured workflow.